Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Morita, Norimasa*; Hiratsuka, Junichi*; Kuwabara, Chiaki*; Aihara, Teruhito*; Ono, Koji*; Fukuda, Hiroshi*; Kumada, Hiroaki; Harada, Tamotsu*; Imajo, Yoshinari*
Proceedings of 12th International Congress on Neutron Capture Therapy (ICNCT-12), p.18 - 20, 2006/12
Since 2003, group of Kawasaki Medical School has conducted BNCT clinical trials on melanomas at the Kyoto University Research Reactor (KUR) and Japan Research Reactor No.4 (JRR-4). We report 4 patients given BNCT for malignant melanomas, 2 with superficial spreading types on the heel, 1 with mucosal melanoma in the nasal cavity, and 1with a melanoma on the vulva and in the vagina. Although 2 patients experienced normal-tissue damage that exceeded the tolerance level, all the participants were cured within a few months of treatment. BNCT was shown to be a promising treatment for mucosal, as well as for cutaneous, melanomas.
Nakamura, Takemi; Kumada, Hiroaki; Kishi, Toshiaki
Proceedings of 12th International Congress on Neutron Capture Therapy (ICNCT-12), p.535 - 538, 2006/10
no abstracts in English
Kageji, Teruyoshi*; Mizobuchi, Keiji*; Nagahiro, Shinji*; Nakagawa, Yoshinobu*; Kumada, Hiroaki
Proceedings of 12th International Congress on Neutron Capture Therapy (ICNCT-12), p.60 - 61, 2006/10
We compared and evaluated boron neutron capture therapy (BNCT) radiation dose between gold wire measurement and JAERI Computational Dosimetry System (JCDS). Gold wire analysis demonstrates the actual BNCT dose though it dose not reflect the real the maximum and minimum dose in tumor tissue. We can conclude that JCDS is precise and high-reliable dose planning system for BNCT.
Kageji, Teruyoshi*; Mizobuchi, Keiji*; Nagahiro, Shinji*; Nakagawa, Yoshinobu*; Kumada, Hiroaki
Proceedings of 12th International Congress on Neutron Capture Therapy (ICNCT-12), p.62 - 63, 2006/10
We compared and evaluated BNCT radiation dose using JAERI Computational Dosimetry System (JCDS) between BSH-base intra-operative BNCT and BSH, BPA-based non-operative BNCT. In comparison of BNCT radiation dose, BSH-based intra-operative BNCT was 1.4-2.1 times higher than BSH, BPA-basednon-operative BNCT.
Kageji, Teruyoshi*; Mizobuchi, Keiji*; Nagahiro, Shinji*; Nakagawa, Yoshinobu*; Kumada, Hiroaki
Proceedings of 12th International Congress on Neutron Capture Therapy (ICNCT-12), p.35 - 36, 2006/10
We analyzed the correlation between boron neutron capture therapy (BNCT) radiation dose and histopathological findings of autopsy or salvage surgery. For the complete remission of glioblastoma (GBM) after BNCT, minimum gross tumor volume (GTV) and clinical target volume (CTV) dose should be 65 and 45 Gy-Eq as a JAERI Computational Dosimetry System (JCDS) dose.
Matsuda, Masahide*; Yamamoto, Tetsuya*; Nakai, Kei*; Endo, Kiyoshi*; Kumada, Hiroaki; Kageji, Teruyoshi*; Matsumura, Akira*
Proceedings of 12th International Congress on Neutron Capture Therapy (ICNCT-12), p.40 - 42, 2006/10
To describe the failure patterns and survival seen with high-grade glioma treated with BNCT, the dose distribution and the clinical responses were retrospectively analyzed. BSH-based BNCT was performed in 12 patients with high-grade glioma (grade IV 7, grade III 5). The post-diagnosis median survival time of 12 patients was 19.8 months (range 3.3-47.2). Four cases of local control, 3 of local recurrence, 3 of distant intraparenchymal recurrence and 2 of subarachnoid dissemination were recorded. According to the analysis of the failure patterns, minimum GTV dose of 26 GyEq or more is necessary for local control.
Ishikawa, Masayori*; Ono, Koji*; Matsumura, Akira*; Yamamoto, Tetsuya*; Hiratsuka, Junichi*; Miyatake, Shinichi*; Kato, Itsuro*; Sakurai, Yoshinori*; Kobayashi, Toru*; Kumada, Hiroaki; et al.
Proceedings of 12th International Congress on Neutron Capture Therapy (ICNCT-12), p.397 - 400, 2006/10
An ultraminiature thermal neutron monitor which was named SOF detector (Scintillator with Optical Fiber detector) had been developed for BNCT treatment. We had been experienced 15 clinical trials using SOF detector until the end of 2005, some measurements got good results, and some got unacceptable results. One reason of the unacceptable results was due to dislocation of the detector during treatment. This is because it is difficult to fix the SOF detector on patient's skin without strong sticker. To overcome this problem, a loop-type SOF probe was developed. By using the loop-type SOF detector, fixing on the patient's skin was much easier.